Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Shinyaku: Pharm. Sales Up 3.6% Driven by Mainstay Products
May 31, 2010
- Bayer Initiates PIII of Regorafenib in mCRC
May 31, 2010
- Kissei: Sales Down 3.7%, Off-Patent Products Struggle
May 31, 2010
- Sosei Initiates PIII for QVA149
May 31, 2010
- Medipal: Sales Up 3.3% to ¥2,546 Bil.
May 31, 2010
- 9-Valent HPV Vaccine under Development in Japan: Banyu
May 31, 2010
- Fully Explain Characteristics of Asthma to Patients to Improve Compliance: Prof. Ohta
May 31, 2010
- Alfresa HD: Sales Up 6.4% to ¥2,059.2 Bil.
May 31, 2010
- Roche, Biogen Idec Discontinue Development of Ocrelizumab for RA
May 31, 2010
- 2 Advanced Therapies Recommended for Combination with Insurance-Covered Therapies
May 31, 2010
- Suzuken: Operating Profits Down 14.5% Despite 4.9% Increase in Sales
May 31, 2010
- Insomnia Increases Risk of Diabetes: Prof. Watanabe
May 31, 2010
- Crestor Indicated in EU for Prevention of Major CV Events: AZ
May 31, 2010
- Toho HD: Sales Top \1 Trillion Benchmark
May 31, 2010
- Takeda President Yasuchika Hasegawa Elected JPMA President
May 31, 2010
- Settle Prices on a Product-by-Product Basis: Mr Matsutani
May 31, 2010
- JPMA Proposes Specific Measures for Growth Strategy
May 31, 2010
- Korosho Completes Hearings of Wholesalers on Changes in Business Practice
May 31, 2010
- MTPC: Pharma Sales Up 2.2% Driven by Remicade
May 24, 2010
- GSK's Ofatumumab Receives Conditional Approval in EU
May 24, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…